Health care stocks in the Russell 3000 index of the largest U.S. companies are outperforming the index as a whole since the election. A few stocks with ACA exposure are down since the election, but many more are up.
Donald Trump has gone from terrifying the pharma industry with pricing criticism to increasingly conspicuous silence. A White House budget plan released this week essentially ignored drug pricing.
The fight over the ACA and individual exchanges concerns a relatively small portion of the market -- but the GOP's proposed shift in tax policy would have a far bigger impact on insurers and employers.
While other big insurers were relatively slow to pull back from the ACA's individual insurance exchanges as their losses mounted, UnitedHealth started taking steps to limit its losses in late 2015 and announced a near-total exit in April 2016.
Even if Trump ends up being a pharma friend, it's worth remembering that some of the biggest pricing pressures the industry faces come from the private sector, and they're growing in severity.